Trial
NCT02863055
Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators
—
Condition
Malignant Pleural Mesothelioma
Intervention
Nintedanib
Why stopped
lack of scientific relevance (change in the treatment landscape) and poor recruitment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-19